OPEN ACCESS Freely available online

Journal of Thyroid Disorders & Therapy

Commentary

Integrating Genomics and Artificial Intelligence in Thyroid Cancer Prognostication

Wenk Tokopi*

Department of Medicine, University of Cambridge, Cambridge, UK

DESCRIPTION

Thyroid cancer is one of the most rapidly increasing cancers worldwide, with a generally favorable prognosis compared to other malignancies. Predicting the course of the disease and the outcomes of patients is made extremely difficult by its heterogeneity. While histological examination and clinical staging are useful tools, they are not always effective in properly identifying recurrence or prognosticating aggressive patients. Artificial Intelligence (AI) and genomics together provide a revolutionary approach to thyroid cancer prognostication, allowing for more accurate risk assessment and individualized treatment plans.

The role of genomics in thyroid cancer

Genomic profiling has revolutionized our understanding of thyroid cancer by uncovering the molecular underpinnings of the disease. Tumour subtypes related to thyroid cancer are linked to several genetic changes, including copy number variations, fusions and mutations in genes including BRAF, RAS and RET/PTC. These changes affect tumour aggressiveness, behaviour and responsiveness to treatment in addition to being the primary cause of carcinogenesis.

For example, resistance to radioactive iodine treatment and increased rates of recurrence are linked to the BRAFV600E mutation, which is common in Papillary Thyroid Cancer (PTC) and is associated with worse results. A more aggressive phenotype is also indicated by the frequent association of RAS mutations with Poorly Differentiated Thyroid cancer (PDT) and Follicular Thyroid Carcinoma (FTC). Identification of high-risk individuals who could benefit from more intensive therapy or closer monitoring can be facilitated by an understanding of these genetic changes. Translation of these discoveries into clinical practice is hindered, despite these advances, by the sheer number and complexity of genetic data. AI can be quite helpful in incorporating genomic data for more precise prognostication in this situation because of its capacity to handle and analyse massive datasets.

Applications and benefits of integrating genomics and AI

In terms of thyroid cancer prognosis and treatment, the combination of genomics and AI has several advantages. Creating customized risk scores that use clinical and genetic information to forecast the chance of illness progression and recurrence is one important use. Determining whether extensive surgical intervention or adjuvant therapy is necessary can be guided by these risk ratings. The discovery of new therapeutic targets is another use. Large genomic datasets may be analyzed by AI to find previously unknown molecular pathways involved in the development of thyroid cancer. Because of this, more effective and less harmful tailored medicines may be created than those resulting from traditional medical interventions. AI-driven models may also be used to forecast how well a patient will respond to treatments like tyrosine kinase inhibitors or radioactive iodine therapy. This can assist in determining the best course of action for certain individuals, enhancing results and cutting down on pointless procedures.

CONCLUSION

A potential area of personalized medicine is the combination of AI and genomics in the prognostication of thyroid cancer. We can create more precise and individualized prognostic models by fusing the analytical capacity of AI with the in-depth biological insights that genomics has to offer. These developments might lead to better patient outcomes, more effective treatment plans and the creation of modern treatments for thyroid cancer. Realizing the full potential of this transformational strategy will depend on overcoming present obstacles as research in this subject progresses.

Correspondence to: Wenk Tokopi, Department of Medicine, University of Cambridge, Cambridge, UK, E-mail: Wenk@tok.uk

Received: 26-Aug-2024, Manuscript No. JTDT-24-34207; **Editor assigned:** 29-Aug-2024, PreQC No. JTDT-24-34207 (PQ); **Reviewed:** 12-Sep-2024, QC No. JTDT-24-34207; **Revised:** 19-Sep-2024, Manuscript No. JTDT-24-34207 (R); **Published:** 26-Sep-2024, DOI: 10.35841/2167-7948.24.13.343

Citation: Tokopi W (2024). Integrating Genomics and Artificial Intelligence in Thyroid Cancer Prognostication. Thyroid Disorders Ther. 13.343.